PE20121045A1 - Agonista de gpr119 - Google Patents

Agonista de gpr119

Info

Publication number
PE20121045A1
PE20121045A1 PE2012000041A PE2012000041A PE20121045A1 PE 20121045 A1 PE20121045 A1 PE 20121045A1 PE 2012000041 A PE2012000041 A PE 2012000041A PE 2012000041 A PE2012000041 A PE 2012000041A PE 20121045 A1 PE20121045 A1 PE 20121045A1
Authority
PE
Peru
Prior art keywords
methyl
gpr119 agonist
metansulfonil
piperidin
tetrahydro
Prior art date
Application number
PE2012000041A
Other languages
English (en)
Spanish (es)
Inventor
Melendo Ana Belen Bueno
Jeffry Bernard Franciskovich
Bin Liu
Kumiko Takeuchi
David Gene Barrett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20121045A1 publication Critical patent/PE20121045A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
PE2012000041A 2009-07-15 2010-07-12 Agonista de gpr119 PE20121045A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24

Publications (1)

Publication Number Publication Date
PE20121045A1 true PE20121045A1 (es) 2012-08-09

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000041A PE20121045A1 (es) 2009-07-15 2010-07-12 Agonista de gpr119

Country Status (24)

Country Link
US (1) US8207344B2 (OSRAM)
EP (1) EP2454251A1 (OSRAM)
JP (1) JP5715127B2 (OSRAM)
KR (1) KR101365854B1 (OSRAM)
CN (1) CN102471313B (OSRAM)
AR (1) AR077638A1 (OSRAM)
AU (1) AU2010273642B2 (OSRAM)
BR (1) BRPI1015921A2 (OSRAM)
CA (1) CA2764906C (OSRAM)
CO (1) CO6480977A2 (OSRAM)
CR (1) CR20120012A (OSRAM)
DO (1) DOP2012000006A (OSRAM)
EA (1) EA020540B1 (OSRAM)
EC (1) ECSP12011606A (OSRAM)
IL (1) IL216776A0 (OSRAM)
MA (1) MA33428B1 (OSRAM)
MX (1) MX2012000704A (OSRAM)
NZ (1) NZ597125A (OSRAM)
PE (1) PE20121045A1 (OSRAM)
SG (1) SG177646A1 (OSRAM)
TN (1) TN2012000002A1 (OSRAM)
TW (1) TWI429634B (OSRAM)
WO (1) WO2011008663A1 (OSRAM)
ZA (1) ZA201200227B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1599468E (pt) 2003-01-14 2008-01-14 Arena Pharm Inc Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US20140018371A1 (en) * 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
AU2012240122B2 (en) 2011-04-08 2016-08-25 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2760855B1 (en) * 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
US9944600B2 (en) * 2012-06-12 2018-04-17 Chong Kun Dang Pharmaceutical Corp. Piperidine derivatives for GPR119 agonist
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
EP3074384B1 (en) 2013-11-26 2019-05-22 Chong Kun Dang Pharmaceutical Corp. Amide derivatives for gpr119 agonist
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
DK3310760T3 (da) 2015-06-22 2022-10-24 Arena Pharm Inc Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1599468E (pt) * 2003-01-14 2008-01-14 Arena Pharm Inc Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
AU2007291252A1 (en) * 2006-08-30 2008-03-06 Inovacia Ab Pyridine compounds for treating GPR119 related disorders
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN101801954B (zh) 2007-09-20 2013-10-09 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物

Also Published As

Publication number Publication date
IL216776A0 (en) 2012-03-01
TN2012000002A1 (en) 2013-09-19
CA2764906A1 (en) 2011-01-20
TWI429634B (zh) 2014-03-11
NZ597125A (en) 2013-08-30
CO6480977A2 (es) 2012-07-16
CA2764906C (en) 2014-06-10
EA020540B1 (ru) 2014-11-28
CR20120012A (es) 2012-03-28
WO2011008663A1 (en) 2011-01-20
MA33428B1 (fr) 2012-07-03
ECSP12011606A (es) 2012-02-29
AU2010273642A1 (en) 2012-01-19
CN102471313B (zh) 2014-06-04
AU2010273642B2 (en) 2014-03-13
SG177646A1 (en) 2012-02-28
MX2012000704A (es) 2012-03-07
KR101365854B1 (ko) 2014-02-21
EA201270169A1 (ru) 2012-06-29
DOP2012000006A (es) 2012-01-31
JP2012533546A (ja) 2012-12-27
AR077638A1 (es) 2011-09-14
US8207344B2 (en) 2012-06-26
BRPI1015921A2 (pt) 2016-04-26
CN102471313A (zh) 2012-05-23
JP5715127B2 (ja) 2015-05-07
EP2454251A1 (en) 2012-05-23
TW201114757A (en) 2011-05-01
US20110015199A1 (en) 2011-01-20
KR20120024964A (ko) 2012-03-14
ZA201200227B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
PE20121045A1 (es) Agonista de gpr119
PE20090449A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20130039A1 (es) Pirazoles fungicidas
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20080525A1 (es) Derivados de imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo como moduladores del receptor canabinoide 1 (cb1r)
PE20090774A1 (es) Compuestos heterociclicos como moduladores de la enzima dgat1
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20141307A1 (es) Aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2)
EA201001358A1 (ru) Активаторы глюкокиназы
PE20090610A1 (es) Derivados de pirazol sustituidos
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
UY32606A (es) Sulfonamidas nematocidas
PE20142099A1 (es) Derivados de sulfonamida
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
ATE473229T1 (de) Tricyclische verbindungen und deren verwendung als mglur1-antagonisten
ATE555096T1 (de) Heterocyclische verbindungen als viruzide
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20081467A1 (es) Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk)
PE20090772A1 (es) Derivados de bencimidazol
DK2076506T3 (da) Heterocyklisk substituerede piperidiner som ORL-1-ligander
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed